GlassScriptPhysician profile
Deryk Lee Mcdowell
NPI 1356486179
$3,384.92
in general payments reported to CMS, 2019-2025
17 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $184 · 2021: $581 · 2022: $628 · 2023: $542 · 2024: $567 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $852.00 | 2019-2025 | Jot Dx, Tendril, Aveir |
| Boston Scientific Corporation | $647.54 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Medtronic, INC. | $461.46 | 2021-2025 | Micra, Linq II, Cardioblate Cryoflex |
| Siemens Medical Solutions USA, INC. | $448.78 | 2023-2025 | Acuson Origin Diagnostic Ultrasound System |
| Medtronic Vascular, INC. | $287.16 | 2019-2020 | |
| Biosense Webster, INC. | $134.27 | 2022-2025 | Carto 3 |
| Actelion Pharmaceuticals US, INC. | $133.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $108.83 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $84.62 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.81 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $50.24 | 2020-2021 | |
| Amgen INC. | $37.96 | 2023-2024 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $20.00 | 2023 | Arcalyst |
| Abiomed | $18.75 | 2023 | Impella |
| Kestra Medical Technology Services, INC. | $16.82 | 2023 | Assure Wcd |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.28 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $13.85 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deryk Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.